Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study

    Primary Author / Presenter(s)

  • Thomas J. Kipps, MD, PhD

    Distinguished Professor of Medicine, Co-Director, Hematology Malignancy Program; Director, Center for Novel Therapies; Evelyn and Edwin Tasch Chair in Cancer Research
    UC San Diego, Moores Cancer Center
    San Diego, California, United States

    • Co-Author(s)

  • FA

    Farrukh T. Awan, MD

    Associate Professor and Director of Lymphoid Malignancies Program at UTSW
    The University of Texas Southwestern
    Dallas, Texas, United States

  • Barbara Eichhorst, MD

    Associate Professor, Consultant Hematologist
    Department I of Internal Medicine, University Hospital of Cologne
    Cologne, Germany

  • Yair Herishanu, MD

    Head of CLL Unit; Director, Hematology Clinic
    Tel Aviv Sourasky Medical Center
    Tel-Aviv, Tel Aviv, Israel

  • Wojciech Jurczak, MD, PhD

    Consultant, Head of Dpt of Lymphoid Malignancies
    Maria Skłodowska-Curie National Research Institute of Oncology
    Kraków, Malopolskie, Poland

  • DL

    David Lavie, MD

    Hadassah Medical Center
    Jerusalem, Yerushalayim, Israel

  • NM

    Nicolas Martinez-Calle

    Consultant Haematology
    Nottingham University Hospitals, NHS Trust
    Nottingham, England, United Kingdom

  • AM

    Andras Masszi, MD

    Országos Onkológiai Intézet
    Budspest, Budapest, Hungary

  • Carolyn J. Owen, MD

    Associate Professor
    Arthur J. E. Child Comprehensive Cancer Centre
    Calgary, Canada

  • CP

    Christian Bjørn Poulsen, MD

    Zealand University Hospital, Roskilde
    Roskilde, Sjelland, Denmark

  • CS

    Christof Schneider, MD

    MD
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Baden-Wurttemberg, Germany

  • YX

    Yan Xu

    1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
    Tianjin, China (People's Republic)

  • JY

    Jing Yang, PhD

    Clinical Director
    Merck & Co., Inc.
    Rahway, New Jersey, United States

  • MF

    Mohammed Z. Farooqui, Phd

    Executive Director
    Merck & Co., Inc.
    Rahway, New Jersey, United States

  • JK

    Jaimal Kothari, MD

    GenesisCare – Oxford
    Oxford, England, United Kingdom